IMM 20065
Alternative Names: IMM-20065Latest Information Update: 28 Mar 2024
At a glance
- Originator Immunome
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 12 Feb 2020 Preclinical trials in Cancer in USA (Parenteral) (Immunome pipeline February 2020)
- 24 Jul 2019 Early research in Cancer in USA (Parenteral) (Immunome pipeline, July 2019)